Embargoed until 8:39 a.m. CT/9:39 a.m. ET, Sunday, Nov. 6, 2022
DALLAS, Nov. 6, 2022 — The immediate use of veno-arterial mechanical circulatory extracorporeal membrane oxygenation (ECMO) devices to support adults with rapidly deteriorating or severe cardiogenic shock was feasible but did not improve clinical outcomes compared to people who received early conservative therapy, according to late-breaking clinical trial results presented today at the American Heart Association’s Scientific Sessions 2022. The meeting, held in person in Chicago and virtually, Nov. 5-7, 2022, is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science.
Cardiogenic shock occurs when the heart cannot pump enough blood and oxygen to the brain and other vital organs. Treatment for patients with cardiogenic shock includes the administration of medications such as inotropes and vasopressors. Inotropes alter the force of the heart’s contractions, and vasopressors constrict blood vessels to raise blood pressure. ECMO life support machines may also be used to support blood circulation by pumping and oxygenating a patient's blood outside the body, allowing the heart and lungs to rest.
“ECMO is a widely available, minimally invasive, short-term mechanical circulatory support device that enables rapid restoration of circulation and blood flow to organs,” said Petr Ostadal, M.D., Ph.D., a professor of medicine in the department of cardiology at Na Homolce Hospital in the Czech Republic. “ECMO is increasingly used for circulatory support in people with cardiogenic shock or cardiac arrest, yet current evidence on the implementation of ECMO to stabilize hemodynamic conditions in these patients remains insufficient.”
The ECMO-CS Trial is the first multicenter, randomized clinical study focused on the use of ECMO in people with severe or rapidly progressing cardiogenic shock. The study included 117 adults with an average age of 65 years, and approximately 75% of the patients were male adults. Participants were randomized to two groups: the ECMO group or the early conservative therapy group, and their baseline clinical parameters were comparable at randomization: they had similar lactate levels and median mean arterial pressure..
In the conservative therapy group, an ECMO may have been used later in case of worsening hemodynamic status. All other diagnostic and therapeutic procedures were performed according to the current standards of care, including treatment with other cardiovascular interventions or mechanical circulatory support devices, as needed.
The results found that the clinical outcomes of patients receiving early conservative therapy with inotropes and vasopressors were similar to those in the immediate ECMO use group:
- Within 30 days of experiencing severe or rapidly progressing cardiogenic shock, 64% of patients who received early ECMO therapy died, required cardiac resuscitation or needed additional mechanical circulatory support, compared to 71% of people who received early conservative care.
- Mortality rates at 30 days were comparable between both groups (50% vs. 48%, respectively).
- Serious adverse events, such as bleeding, leg ischemia, stroke, pneumonia and sepsis, occurred in 60% of patients in the ECMO group and 61% of those in the early conservative group.
- Fewer patients in the ECMO group required another form of mechanical circulatory support when compared to those in the early conservative group (17% vs. 42%, respectively).
- 39% of patients who received early conservative therapy required ECMO support later in the course of intensive care.
“We expected to see a significant improvement in outcomes for patients with severe or rapidly progressing cardiogenic shock who underwent early ECMO treatment, and we were surprised to find that immediate use of ECMO was actually not superior to early conservative therapy,” Ostadal said.
The study’s limitations included that the trial did not compare ECMO implementation with conservative therapy, rather, it compared an early ECMO strategy with early conservative strategy permitting “bail-out” ECMO therapy in cases of worsening hemodynamic status. In addition, the trial was not blinded and it had a limited sample size. Also, the exclusion criteria included several conditions that may cause or influence cardiogenic shock (e.g., cardiac tamponade, pulmonary emboli, cardiac arrest survivors.
Co-authors are Richard Rokyta, M.D., Ph.D.; Jiri Karasek, M.D., Ph.D.; Andreas Kruger, M.D.; Ph.D.; Dagmar Vondrakova, M.D., Ph.D.; Marek Janotka, M.D.; Jan Naar, M.D., Ph.D.; Jana Smalcova, M.D.; Marketa Hubatova, M.Sc.; Milan Hromadka, M.D., Ph.D.; Stefan Volovar, M.D.; Miroslava Seyfrydova, M.D.; Jiri Jarkovsky, Ph.D.; Michal Svoboda, M.Sc.; Ales Linhart, M.D., Ph.D.; and Jan Belohlavek, M.D., Ph.D. Authors’ disclosures are listed in the abstract.
The ECMO-CS trial was supported by a grant from the Agency for the Czech Republic Health Research No. 15-27994A.
Statements and conclusions of studies that are presented at the American Heart Association’s scientific meetings are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. Abstracts presented at the Association’s scientific meetings are not peer-reviewed, rather, they are curated by independent review panels and are considered based on the potential to add to the diversity of scientific issues and views discussed at the meeting. The findings are considered preliminary until published as a full manuscript in a peer-reviewed scientific journal.
The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and biotech companies, device manufacturers and health insurance providers and the Association’s overall financial information are available here.
- Multimedia is available on the right column of the release link https://newsroom.heart.org/news/early-use-of-ecmo-devices-did-not-improve-outcomes-in-people-with-cardiogenic-shock?preview=918f9657873130d3cf2c2d3a505abb7f
- Link to abstract and AHA Scientific Session 2022 Online Program Planner
- Article in Circulation: Heart Failure: Use of Extracorporeal Membrane Oxygenation as Bridge to Replacement Therapies in Cardiogenic Shock: Insights From the Extracorporeal Life Support Organization (December 2021)
- For more news at AHA Scientific Sessions 2022, follow us on Twitter @HeartNews #AHA22
The American Heart Association’s Scientific Sessions 2022 is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science. The 3-day meeting will feature more than 500 sessions focused on breakthrough cardiovascular basic, clinical and population science updates occurring Saturday through Monday, November 5-7, 2022. Thousands of leading physicians, scientists, cardiologists, advanced practice nurses and allied health care professionals from around the world will convene virtually to participate in basic, clinical and population science presentations, discussions and curricula that can shape the future of cardiovascular science and medicine, including prevention and quality improvement. During the three-day meeting, attendees receive exclusive access to more than 4,000 original research presentations and can earn Continuing Medical Education (CME), Continuing Education (CE) or Maintenance of Certification (MOC) credits for educational sessions. Engage in Scientific Sessions 2022 on social media via #AHA22.
About the American Heart Association
The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public’s health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1.